Perrigo (PRGO) reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.During the q ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 ladies and gentlemen, and welcome to the Perrigo Q1 twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/07/2025. I would now like to turn the conference over to Brad Joseph, VP, Global Investor Relations. Please go ahead. Speaker1 Good morning and good afternoon ...

Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this drug company would post earnings of $0.92 per share when it actually produced earnings of $0.93, delivering a surprise of 1.09%.Over the last four quarters, the company has s ...

Q1 2025 Earnings Presentation May 7, 2025 Bradley Joseph VP Investor Relations & Corporate Communications Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or ...

Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor DayDelivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC BrandsWidened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS RangeDUBLIN, May 7, 2025 /PRNewswire/ --First Quarter 2025 Highlights: Net sales of $1.04 billion declined ...

We expect Perrigo Company plc (PRGO) to surpass expectations when it reports first-quarter 2025 earnings on May 7, before the opening bell. The company’s earnings beat estimates by 1.09% in the last reported quarter.The Zacks Consensus Estimate for sales and earnings is pegged at $1.08 billion and 53 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Factors Shaping PRGO’s Upcoming ResultsPerrigo reports its results under two segments: Consumer Self Care ...

In 2015, Mylan made a $29 billion unsolicited bid to acquire Perrigo (NYSE: PRGO ). This offer was later raised to a whopping $34 billion, and yet Perrigo, under then-CEO Joseph Papa, rejected the bid, claiming it “About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requ ...

Core Points - Perrigo Company plc plans to release its first quarter 2025 financial results on May 7, 2025, at 8:30 A.M. (EST) [1] - The earnings conference call will be accessible via webcast and phone, with a replay available from May 7 to May 14, 2025 [2] - Perrigo is a leading provider of Consumer Self-Care Products and OTC health solutions aimed at enhancing individual well-being [3]

J.P. Morgan says Perrigo Company plc’s PRGO first-quarter 2025 earnings will be dominated by commentary on the potential impact of tariffs. The analyst says, “Tariffs could potentially have a significant impact on PRGO’s near-term earnings.”Analysts forecast adjusted earnings of 55 cents per share, with sales of $1.09 billion.Analyst Chris Schott says tariffs could lead the OTC drugs company to a low to mid-single-digit impact on global COGS on an annualized basis, and that the company expects to offset thi ...

Core Insights - Perrigo's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2] - The company's reliance on international markets influences its earnings durability and growth capabilities [2][9] Revenue Performance - Total revenue for the recent quarter was $1.14 billion, a decline of 1.6% year-over-year [4] - Revenue from "All other countries" was $27 million, representing 2.37% of total revenue, with a significant surprise decline of -33.11% compared to expectations of $40.37 million [5] - European revenue was $379.1 million, accounting for 33.30% of total revenue, which was a surprise decline of -9.54% from the consensus estimate of $419.08 million [6] Future Revenue Predictions - Analysts predict total revenue of $1.11 billion for the current fiscal quarter, indicating a 2.3% increase from the previous year [7] - Expected contributions from "All other countries" and Europe are projected to be 3.4% ($38.07 million) and 35.7% ($395.74 million) of total revenue, respectively [7] - For the full year, total annual revenue is expected to reach $4.42 billion, marking a 1.1% increase compared to last year [8] Market Observations - The intricacies of global interdependence and geopolitical factors are closely monitored by analysts, impacting earnings forecasts for companies with international operations [10] - The company's stock has increased by 16.7% over the past month, outperforming the S&P 500, which declined by 4.1% [13]